Retinal Melatonin Suppressor Using Photoluminescent Nanocrystals
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing light therapy devices for conditions like Seasonal Affective Disorder are bulky, require power sources, and expose users to high-intensity light, which can be harmful, while also failing to effectively enhance beneficial wavelengths of light for the retina.
Innovation Solution
The use of photoluminescent materials with nanocrystals, such as quantum dots, applied to eyewear lenses to absorb undesirable wavelengths and emit beneficial blue light directly to the retina, optimizing melatonin suppression without increasing overall luminescence or requiring power sources.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-intensity light is used to suppress melatonin effectively, then melatonin suppression efficacy is improved, but harmful exposure to the eye increases
Solution Approach 1:
The patent changes the wavelength parameter of light from broad-spectrum or non-specific wavelengths to specific blue light wavelengths (460-480 nm) that are most effective for melatonin suppression. This parameter change allows achieving therapeutic efficacy at lower intensities, reducing harmful exposure while maintaining effectiveness
Solution Approach 2:
The patent converts potentially harmful high-intensity broad-spectrum light into beneficial low-intensity wavelength-specific blue light. By using optical filters to select only the therapeutic wavelengths (460-480 nm), the system eliminates harmful UV and excessive visible light while retaining the therapeutic effect on melatonin
2Productivity
If blue light intensity is increased to reduce exposure time, then treatment efficiency is improved, but health hazards from intense light exposure increase
Solution Approach 1:
The patent optimizes the wavelength parameter to 460-480 nm where melatonin receptors have maximum sensitivity. This precise parameter optimization ensures that the full therapeutic effect is achieved at the lowest possible intensity, eliminating the need to increase intensity to reduce exposure time
3Ease of operation
If existing light therapy devices are made portable with batteries, then ease of operation is improved, but device complexity increases
Solution Approach 1:
The patent extracts only the essential therapeutic function (blue light emission at 460-480 nm) from complex light therapy devices. By using simple LED components with optical filters rather than full-spectrum light sources and complex control systems, the device achieves portability without requiring batteries or complex power management
Solution Approach 2:
The patent uses passive optical filtering rather than active electronic control systems. The optical filters automatically select the therapeutic wavelengths without requiring electronic sensors, processors, or power sources, eliminating the need for batteries and complex circuitry while maintaining portability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This solution provides a cosmetically acceptable, wearable device that enhances exposure to beneficial light wavelengths, reducing health hazards and improving treatment efficacy for conditions like Seasonal Affective Disorder without the need for bulky devices or high-intensity fluxes.
Implementation Method 1
a photoluminescent material with nanocrystals, such as quantum dots or other fluorescent nanoparticles, each capable of absorbing photons at a first (potentially undesirable) wavelength and emitting the absorbed energy at a second, desired wavelength
Implementation Method 2
a filter layer selected and configured to attenuate at least a portion of the desired or selected wavelengths of light emitted by the photoluminescent material
Data Source
AI summary
This disclosure relates to the application of a photoluminescent material with a plurality of nanocrystals, such as quantum dots or Cornell dots, each capable of absorbing electromagnetic energy at a first wavelength and emitting the absorbed energy as a desired wavelength in the direction of a human retina. Preferably, the emitted wavelength is chosen for its ability to suppress naturally occurring melatonin, i.e., blue light. The disclosure also contemplates the placement of the photoluminescent material over the entire surface of a lens or on a portion of the lens to optimize the exposure to the desired wavelength while reducing the overall luminescence. Finally, the photoluminescent material can be applied as a coating, as part of a material applied to the lens, either superficially or in/within the lens, as part of eyewear, or even as an optical treatment system.